Highly Specialized Fill and Finish

For more than 20 years, Goodwin Biotechnology has developed into a uniquely qualified CDMO that provides a Single Source Solution™ for  clients by offering cell line development,  exploratory proof-of-concept projects through Process Development and cGMP manufacturing of monoclonal antibodies, recombinant proteins, vaccines, and biologic drug conjugates including antibody drug conjugates (ADCs) for small startup ventures to large, multi-national companies as well as government agencies and medical institutions for early and late stage clinical trials. As part of their integrated services offerings, Goodwin Biotechnology operates an ISO5 cGMP filling suite that can accommodate liquid filling of a wide range of configurations to meet specific and unique client requirements.

Downstream Purification Expertise is Critical

Process Development

Goodwin Biotechnology's downstream process development group has well over 50 years of experience in developing and refining purification processes for recombinant proteins. With an extensive background in the purification of proteins from mammalian, as well as plant and animal transgenic systems, Goodwin Biotechnology can quickly develop a purification process for clients that will maximize yields for the target molecule, meet required purity levels, and be compliant with the regulatory requirements for product's development status.

ENHANCING ADCs TO TARGET DISEASED CELLS AND DELIVER PAYLOADS

Insulin-like growth factor or IGF is a natural growth hormone, which plays an important role in normal growth and development. Six soluble insulin-like growth factor-binding proteins or IGFBPs and IGFBP proteases regulate its actions. These binding proteins bind to Insulin-like growth factor with high affinity and specificity[1].

An Overview of the General Cell Culture Work at Goodwin Biotechnology

Goodwin Biotechnology is a leading biological Contract Manufacturing Organization (CMO) that offers a full range of mammalian cell culture services ranging from the creation of up and downstream processes sufficient for the manufacturing of proof of concept, toxicology product material and processes for licensed manufacturing.